2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1394

Comparison of Improvements in Disease Activity between Classes of Biologic Disease Modifying Anti-Rheumatic Drugs in Routine Clinical Practice: Findings from a Large Contemporaneous Real World Cohort
Abstract Number: 1395

Patient Reported Outcomes in Rheumatoid Arthritis: Best Domain, Best Interface
Abstract Number: 1396

Can 3 0-10 Physician Visual Analog Scales (VAS) to Assess Levels of Inflammation, Damage and Distress Offer Comprehensive Quantitative Data That May be As Informative As Detailed, Formal Swollen and Tender Joint Counts?
Abstract Number: 1397

American College of Rheumatology Response Rates Determined Using 28 Versus 68/66 Joint Count in Patients with Rheumatoid Arthritis Receiving Tofacitinib in Phase 3 Studies
Abstract Number: 1398

Sleep and Physical Activity: An Objective Profile of People with Rheumatoid Arthritis
Abstract Number: 1399

Tissues Are Differently Modulated By Tocilizumab and Methotrexate; Assessment of Connective Tissue Metabolites in the Ambition Study
Abstract Number: 1400

Beneficial Effect of Anti-IL-6 Blockade on Insulin Resistance and Insulin Sensitivity in Patients with Rheumatoid Arthritis
Abstract Number: 1401

Persistence of Mast Cell-Rich Synovitis Is Associated with Lack of Response to Synthetic Disease Modifying Anti-Rheumatic Drugs in Patients with Early Rheumatoid Arthritis
Abstract Number: 1402

In RA, Becoming Seronegative over the 1st Year of DMARD Treatment Does Not Improve Chances of Drug-Free Remission in the Long-Term
Abstract Number: 1403

Mediterranean Diet Is Inversely Associated with Risk of Rheumatoid Arthritis: A Swedish Population Based Case-Control Study
Abstract Number: 1404

Hydrogen Sulfide Metabolism and Rheumatoid Arthritis
Abstract Number: 1405

Using Flow and Mass Cytometry to Demonstrate Robust Tissue Processing to Query Molecular Heterogeneity in Phase 1 of the Accelerating Medicines Partnership (AMP) – RA Network
Abstract Number: 1406

Methods for Generating Multiple High-Dimensional Analyses of Cryopreserved Synovial Tissue Developed By the Accelerating Medicines Partnership RA/SLE Network
Abstract Number: 1407

Huntingtin Interactin Protein 1 (HIP1) Regulates Invasiveness, Actin Filament and Lamellipodia Formation in Rheumatoid Arthritis Fibroblast-like Synoviocytes (FLS)
Abstract Number: 1408

The Cation Channel TRPV2 Decreases Rheumatoid Arthritis Fibroblast-like Synoviocyte Invasiveness By Inhibiting RhoA Activation, Cell Adhesion and Actin Cytoskeleton Changes

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].